Wall Street Zen Upgrades Maze Therapeutics (NASDAQ:MAZE) to "Hold"

Key Points

• Maze Therapeutics was upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, amidst various other analyst ratings reflecting a consensus of "Buy" with a target price of $25.60.
• The stock showed a 1.1% increase and has a current trading price of $13.50, with a twelve-month high of $19.19 and a low of $6.71.
• Institutional investors have shown interest in Maze Therapeutics, with multiple hedge funds acquiring new positions valued at significant amounts during the first and second quarters.

Wall Street Zen upgraded shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) from a sell rating to a hold rating in a report released on Saturday morning.

MAZE has been the subject of several other research reports. Wedbush initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective for the company. HC Wainwright started coverage on shares of Maze Therapeutics in a research report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $25.60.

Maze Therapeutics Trading Up 1.1%

Shares of Maze Therapeutics stock traded up $0.15 during midday trading on Friday, reaching $13.50. 69,380 shares of the company's stock traded hands, compared to its average volume of 199,041. The firm has a 50 day moving average of $13.94. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its position in shares of Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock worth $57,000 after purchasing an additional 3,774 shares during the period. Frazier Life Sciences Management L.P. lifted its position in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after acquiring an additional 438,274 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Maze Therapeutics during the 2nd quarter valued at $125,000. Bank of America Corp DE lifted its position in shares of Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock valued at $71,000 after acquiring an additional 1,455 shares during the period. Finally, CW Advisors LLC acquired a new position in shares of Maze Therapeutics during the 2nd quarter valued at $371,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.